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Background: The causal association between depression, anxiety, and health-related quality 
of life (HRQoL) in chronic obstructive pulmonary disease (COPD) is unclear. We therefore 
conducted a systematic review of prospective cohort studies that measured depression, anxiety, 
and HRQoL in COPD.
Methods: Electronic databases (Medline, Embase, Cumulative Index to Nursing and Allied 
Health Literature [CINAHL], British Nursing Index and Archive, PsycINFO and Cochrane 
database) were searched from inception to June 18, 2013. Studies were eligible for inclusion 
if they: used a nonexperimental prospective cohort design; included patients with a diagnosis 
of COPD confirmed by spirometry; and used validated measures of depression, anxiety, and 
HRQoL. Data were extracted and pooled using random effects models.
Results: Six studies were included in the systematic review; of these, three were included in the 
meta-analysis for depression and two were included for the meta-analysis for anxiety. Depression 
was significantly correlated with HRQoL at 1-year follow-up (pooled r=0.48, 95% confidence 
interval 0.37–0.57, P,0.001). Anxiety was also significantly correlated with HRQoL at 1-year 
follow-up (pooled r=0.36, 95% confidence interval 0.23–0.48, P,0.001).
Conclusion: Anxiety and depression predict HRQoL in COPD. However, this longitudinal 
analysis does not show cause and effect relationships between depression and anxiety and 
future HRQoL. Future studies should identify psychological predictors of poor HRQoL in 
well designed prospective cohorts with a view to isolating the mediating role played by anxiety 
disorder and depression.
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Background
Chronic obstructive pulmonary disease (COPD) is responsible for approximately 
5% of deaths worldwide and is predicted to become the third leading cause of death 
by 2030.1 It is a chronic respiratory disease that typically results in a wide range 
of  extrapulmonary comorbidities, such as cardiovascular disease, skeletal muscle 
 dysfunction, osteoporosis, diabetes, anemia, and depression.2,3 COPD severity has 
traditionally been assessed using measures of airflow obstruction, such as forced 
expiratory volume in one second (FEV
1
). However, the therapeutic focus in COPD has 
started to shift away from an emphasis on lung function and mortality to  management 
of comorbidities and more patient-centered outcomes related to functioning and health 
status. This trend is reflected in the increased use and reliance on patient-centered 
outcomes such as health-related quality of life (HRQoL) to assess the impact of 
therapeutic strategies in COPD.4
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HRQoL is a multidimensional concept that refers to 
quality of life that is directly related to health or illness. 
It often includes domains related to the physical, social, 
and psychological impact of illness.5 HRQoL is concerned 
with a patient’s experience of illness and can be defined as 
the subjective perception of the impact of health status on 
 satisfaction with daily life.5–7 COPD severity is associated 
with impaired HRQoL,8–10 but poor HRQoL can also exac-
erbate symptoms of COPD (such as breathlessness) and can 
have a significant impact on physical functioning, the prob-
ability of hospital admission, and mortality.11–18
There are a range of psychological factors that might 
explain variation in respiratory-specific HRQoL over and 
above markers of disease severity, such as FEV
1
.  Depression 
and anxiety have both been found to be important  predictors 
of HRQoL in cross-sectional studies,19–24 with anxiety 
explaining over 40% of the variance in HRQoL in some 
cases.20 Tsiligianni et al conducted a meta-analysis of cross-
sectional studies and reported that depression and anxiety 
were highly correlated with respiratory-specific HRQoL; 
a higher correlation was only found between dyspnea and 
HRQoL.25 Further studies conducted since this review have 
confirmed this finding,26 with one population-based study in 
Singapore showing that the impact of depression on HRQoL 
in COPD was significantly greater than in people without 
COPD.27 Some cross-sectional studies have also examined 
the association between psychological health and more 
generic measures of HRQoL, such as the Medical Outcomes 
Study Short Form.28 However, even when HRQoL is mea-
sured using these generic measures, depression and anxiety 
still account for a significant proportion of the variance in 
people with COPD.29,30
Findings to date are thus mainly derived from cross-sectional 
studies, and although results suggest that there is a significant 
association between depression, anxiety, and HRQoL in COPD, 
they are not able to determine causal associations between these 
factors. It is important to consider the temporal and causal 
association between depression and/or anxiety and HRQoL in 
order to inform the development of future interventions aimed at 
improving HRQoL. We have therefore conducted a systematic 
review with meta-analysis of longitudinal prospective studies 
to assess the ability of depression and anxiety to predict future 
HRQoL in patients with COPD.
Methods
The methods and results for this review are reported in line 
with the PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) guidelines.31
Information sources and search strategy
Studies were identified for inclusion in this review by  searching 
the following electronic databases from inception to June 18, 
2013: Medline, Embase, Cumulative Index to Nursing and 
Allied Health Literature (CINAHL), British  Nursing Index and 
Archive, PsycINFO, and Cochrane database. The search strat-
egy was designed using Medical Subject Headings (MeSH) 
terms and key words relating to COPD, depression, anxiety, 
panic, HRQoL, and longitudinal cohort studies for each data-
base. Electronic searches were supplemented by hand searches 
of reference lists of included papers and relevant reviews.
eligibility criteria
Studies were eligible for inclusion in this review if they:
•	 used a nonexperimental prospective cohort design
•	 did not include any standardized experimental  intervention; 
this was to ensure that samples included in the review had 
not been exposed to any intervention which may have 
modified the association between depression, anxiety, 
and HRQoL over the duration of the study
•	 included patients with a diagnosis of COPD confirmed 
by spirometry as an FEV
1
/forced vital capacity ratio 
,0.70 or FEV
1
 ,80% of the predicted values accord-
ing to GOLD (Global initiative for chronic Obstructive 
Lung Disease) criteria;32 studies that included a cohort of 
patients with a range of chronic physical health problems 
including COPD were eligible only where data for COPD 
confirmed by spirometry were reported separately
•	 used validated self-report measures of either general or 
respiratory-specific HRQoL
•	 used validated diagnostic clinical interviews or  self-report 
measures of depression and anxiety; clinical and subthresh-
old symptoms of depression and anxiety were included.
Studies where depression and anxiety were measured 
using a subscale of a quality of life measure were excluded. 
Studies were not excluded by date of publication, sample size, 
or follow-up period. However, studies that were unpublished, 
published in abstract form only, or were not published in the 
English language were not included in this review.
Study selection
Titles and abstracts were screened (by AB) and full papers 
of potentially relevant abstracts were retrieved. Full text 
versions of abstracts were independently screened and final 
decisions about eligibility were made at a consensus meeting 
with all review authors. Further information was requested 
from authors of seven papers, of whom five responded to 
provide additional information on their papers.
International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
503
Depression, anxiety, and health-related quality of life in COPD
Data extraction
An electronic form was developed in Microsoft Excel for 
the purpose of data extraction. Data were extracted inde-
pendently by two researchers (AB, CA) who each looked 
at all studies. Data were extracted on study design, method 
and place of recruitment, sample age, sex, smoking history, 
method of COPD diagnosis, and severity classification 
(FEV
1
). Scores for HRQoL depression and anxiety were 
extracted at both baseline and follow-up. Any disagreements 
between researchers were resolved by discussion.
The main aim of this review was to assess the strength 
of the longitudinal association between anxiety, depression, 
and HRQoL in COPD. Where these data were not available 
in the published papers, authors were contacted by email or 
letter to request the appropriate data. Where the length of 
follow-up varied, data were extracted and included in the 
meta-analysis for the time point closest to 12 months after 
the baseline measures were taken.
Quality assessment
Studies were rated for their quality by two researchers 
(AB, CA) using criteria adapted from guidance on the assess-
ment of observational studies33 and the Quality Assessment 
Tool for Quantitative Studies.34 Any disagreements were 
resolved by discussion.
The quality review included assessment of selection bias, 
response bias, the reliability and validity of data collection 
methods, withdrawals and dropouts, and whether confounding 
variables were adequately controlled for. Three key criteria 
were deemed as essential to the quality review and each study 
was awarded one point for each criterion met; this was then 
used as a framework for narrative synthesis of the results. 
These key criteria were: response rate of 70% or greater at 
baseline; control for confounding factors in  analysis; and 
response rate greater than 70% at follow-up.34
Data analysis and synthesis
Data analysis was conducted in Stata (version 12.1; 
 StataCorp LP, College Station, TX, USA) and Comprehensive 
 Meta-analysis (version 2.2.064; BioStat International, Inc., 
Tampa, FL, USA). Where possible, indices of association 
between depression or anxiety and total scores for HRQoL 
measures were included in the meta-analysis. However, where 
total scores were not available, the most appropriate subscale 
score was used. For the St George’s Respiratory Question-
naire (SGRQ)35 the Impact subscale was used because it 
provides a measure of social functioning and psychological 
disturbance associated with respiratory disease.35 We aimed to 
extract regression coefficients where possible. However, since 
regression coefficients were not available in any of the studies, 
correlation coefficients were extracted and transformed for 
meta-analysis using  Fisher’s Z transformation in order to nor-
malize the distribution of r, making the variance independent 
of the unknown true value of the  correlation.36 The Z scores 
were then pooled across the studies using a random effects 
model to account for variation between studies. The pooled 
effect size was then converted back to a correlation coeffi-
cient.37 A pooled correlation coefficient of r=0.10 was consid-
ered small, r=0.25 as moderate, and r=0.40 as large.38 Where 
papers did not report either a correlation coefficient or the data 
required to compute a correlation coefficient, we contacted 
the corresponding author and requested the missing data. Two 
authors responded and supplied the relevant data.39,40 Statisti-
cal heterogeneity was investigated using I2 which measures 
the percentage of the variation across studies that is due to 
heterogeneity and cannot be explained by chance.41 Low 
heterogeneity is indicated by an I2 result of #25%, moder-
ate heterogeneity by around 50%, and high heterogeneity is 
$75%.41
Results
Electronic and hand searches identified 380 citations exclud-
ing duplicates. Of these, 236 citations were excluded on the 
basis that their abstracts did not meet the eligibility criteria 
for this review. The full texts for 144 citations were reviewed. 
Six studies were identified that met the criteria for inclusion 
in the systematic review,39,40,42–45 of which three were eligible 
for inclusion in meta-analysis for depression39,40,43 and two for 
anxiety.39,40 The flow of the studies and reasons for exclusion 
are presented in the PRISMA flow chart in Figure 1.31
Characteristics of studies and populations
The characteristics of each study are summarized in Table 1. 
In total, there were data for 895 COPD patients, of whom 
69.8% (n=625) were male. Five of the studies included both 
male and female COPD patients and one was limited to 
male patients.39 The mean age across the studies ranged from 
64.6 years44 to 73.5 years.42 Length of follow-up ranged from 
3 months40 to 5 years.39
The majority of participants (61.1%, n=547) were 
recruited in hospital following admission for acute 
 exacerbations of COPD.42,43 The remaining 38.9% (n=348) 
were recruited from hospital outpatient settings. One study 
excluded patients who had experienced an acute exacerbation 
in the previous 6 weeks,39 and another reported that none of 
the patients in their sample had been admitted for an acute 
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498 records identified through
database searching (CINAHL,
Embase, Medline, BNI, PsycINFO
and Cochrane database)
11 additional records identified
through other sources
380 records after duplicates removed
380 records screened 236 records excluded
144 full-text articles
assessed for eligibility
138 full-text articles
excluded, with reasons:
n=34 cross sectional
study
n=15 intervention
studies
n=1 qualitative study
n=8 not COPD
n=2 COPD diagnosis
not confirmed by
spirometry
n=6 no separate data for
COPD
n=12 not in English
language
n=11 no measure of
HRQoL
n=16 no measure of
depression of anxiety
n=13 HRQoL and
psychological data not
analysed longitudinally
n=16 conference
abstract/editorial/protocol/
guidelines/narrative
review
n=4 systematic reviews
6 studies included in
synthesis
Figure 1 Search flowchart.
Abbreviations: BNI, British Nursing Index and Archive; CINAHL, Cumulative Index to Nursing and Allied Health Literature; COPD, chronic obstructive pulmonary disease; 
HRQoL, health-related quality of life.
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exacerbation at the time they participated in the study.44 All 
included studies recruited patients with a mean predicted 
FEV
1
 ,50%, which indicates severe COPD.32
Four of the six studies39,40,42,43 measured HRQoL using 
COPD-specific measures, including the SGRQ and the 
Chronic Respiratory Questionnaire.46 One study45 used the 
Sickness Impact Profile,47 and another used both the Sickness 
Impact Profile and the SGRQ.44 Four of the six studies39,40,42,44 
measured symptoms of depression using the Hospital 
 Anxiety and Depression Scale (HADS).48 One study43 used 
the  Hopkins Symptom Checklist,49 and one study used the 
Profile of Mood States.50 Three studies measured anxiety 
symptoms using the HADS.39,40,44 No study measured panic 
disorder or any other specific anxiety disorders.
The prevalence of anxiety and depression varied at 
baseline (Table 1). The three studies that recruited patients 
following an admission to hospital reported that patients in 
their sample were experiencing symptoms of depression 
at baseline.40,42,43 One study reported that 44.4% of their 
sample had symptoms of depression at baseline, but did 
not report mean HADS scores.42 Three of the studies that 
recruited hospital outpatients reported that their sample had 
symptoms of depression that were not clinically significant 
at baseline.39,44,45 However, one study of outpatients reported 
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a significant increase in depressive symptoms in their sample 
over a 5-year study period.39
Three studies measured anxiety using the HADS; two 
were studies of hospital outpatients and neither reported 
clinical levels of anxiety at baseline;39,44 one was a study of 
patients admitted to hospital and discharged to a nurse-led 
early discharge service and reported a mean HADS anxiety 
score of 8.8, indicating mild anxiety symptoms.40,48
Quality of included studies
The results of the quality review are presented in Table 2. The 
quality of the studies varied greatly. One study met the require-
ments for all three of the quality criteria,42 two studies met two 
of the criteria,40,43 and three studies did not meet any.39,44,45 Five 
out of the six studies studies39,40,42,43,45 reported attrition rates 
at follow-up, two of which found that those who completed 
the study were more likely to be younger than those who did 
not.43,45 Furthermore, in one study,39 over 40% of patients who 
did not complete follow-up at 5 years had died. In this study, 
patients who had died were found to be significantly older, 
more breathless, and had worse HRQoL than those who did 
complete follow-up.
Longitudinal association of depression  
with HRQoL in COPD
Six longitudinal cohort studies investigated the association 
between depression and HRQoL in COPD (Table 1), but 
only three studies could be included in the meta-analysis 
for depression.39,40,43
Ng et al42 scored the highest score of 3 in the quality review 
and reported that depressed patients had significantly worse 
HRQoL at baseline across all subscales of the SGRQ, and this 
was maintained at 12-month follow-up. However, the authors 
did not analyze the predictive effect of depression on HRQoL 
across the 12-month period. Two of the studies scored 2 in the 
quality review.40,43 Andenaes et al43 studied patients who were 
admitted to hospital with COPD and reported a significant 
correlation between depression at baseline and HRQoL on 
follow-up at 6 and 9 months. In this study, depression was 
significantly correlated with the respiratory-specific SGRQ 
Impact subscale (r=0.28, n=51, P,0.05, 95% confidence 
interval [CI] not reported) and also the physical domain 
(r=−0.64, n=51, P,0.01, 95% CI not reported), psychologi-
cal domain (r=−0.62, n=51, P,0.01, 95% CI not reported), 
and environmental domain (r=−0.41, n=51, P,0.01, 95% CI 
not reported), but not with the social domain (r=−0.23) of the 
WHOQoL-BREF (World Health Organization Quality of Life 
Instrument). Coventry et al40 found that depression at baseline 
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was significantly correlated with respiratory-specific HRQoL 
at 3 months (r=0.52, P,0.001) and 1-year follow-up (r=0.64, 
P,0.001) in patients discharged from hospital under the care 
of early discharge services (Table 3). Three studies did not 
meet any of the key quality criteria.39,44,45 Firstly, Oga et al39 
reported that depression measured at baseline was signifi-
cantly correlated with respiratory-specific HRQoL at 1-year 
follow-up (r=0.47, P,0.001); this association remained after 
5 years (r=0.47, P,0.001) in the sample of outpatients with 
severe COPD.39 Secondly, Engstrom et al found that depres-
sion as measured by the Hospital Depression and Anxiety 
Scale depression subscale (b=0.39, P,0.001), 6-minute 
walk distance (b=0.05, P,0.05), and vital capacity (b=0.15, 
P,0.001) were the best predictors of HRQoL, explaining 
59% of the variance in multiple regression analyses when 
SGRQ scores were excluded.44 Finally, Graydon et al found 
that negative mood, as measured by the Profile of Mood States 
at baseline, was significantly correlated with HRQoL after 12 
months (r=0.49, P,0.0001, 95% CI not reported).45 However, 
they did not include depression as a predictor variable in their 
multiple regression analyses.
Meta-analysis of longitudinal  
association between depression  
and HRQoL in COPD
Three studies were eligible for inclusion in meta-analysis for 
depression.39,40,43 Random effects meta-analysis of the three 
studies (Figure 2) found a large positive correlation between 
depression at baseline and HRQoL measured at follow-up 
(r=0.48, 95% CI 0.37–0.57, P,0.001). A moderate to high 
degree of heterogeneity was found across the studies (Q=6.60 
df=2, P=0.037, I2=69.7%).41
Longitudinal association of anxiety  
with HRQoL in COPD
Two cohort studies report the longitudinal association 
between anxiety and HRQoL in COPD (Table 4).39,40 
The study by  Coventry et al met two of the key quality cri-
teria for this review and found that anxiety at baseline was 
significantly correlated with respiratory-specific HRQoL at 3 
months (r=0.40, P=0.002) but this did not remain significant 
at 1-year follow-up (r=0.26, P=0.052).40 The second study 
did not meet any of the key quality criteria but reported that 
anxiety was correlated with respiratory-specific HRQoL at 
1-year (r=0.41, P,0.001) and 5-year follow-up (r=0.51, 
P,0.001).39
Meta-analysis of longitudinal association 
between anxiety and HRQoL in COPD
Two studies were eligible for inclusion in the meta-analy-
sis.39,40 The random effects meta-analysis of the two studies 
(Figure 3) found that anxiety at baseline was associated with 
a moderate and significant positive correlation with HRQoL 
at follow-up (r=0.36, 95% CI 0.23–0.48, P,0.001). A low 
degree of heterogeneity was found across the studies (Q=1.22, 
df=1, P=0.269, I2=18.3%).
Discussion
We conducted a systematic review and meta-analysis of 
longitudinal cohort studies to assess the temporal association 
between depression and anxiety and HRQoL in COPD. We 
identified six studies in total, of which three met the criteria 
for inclusion in the meta-analysis. Results indicated that both 
depression and anxiety predict future HRQoL. The associa-
tion was stronger for depression than for anxiety.
Table 3 Longitudinal correlations between depression and HRQoL in chronic obstructive pulmonary disease
Reference Depression  
measure
HRQoL measure Length of  
follow-up
Sample  
size
Correlation  
(r)
P-value
Andenaes et al43 HSCL-25 SGRQ symptoms 9 months 51 −0.079 NS
HSCL-25 SGRQ impact 9 months 51 0.279 ,0.05
HSCL-25 SGRQ activities 9 months 51 −0.138 NS
HSCL-25 wHOQOL physical 9 months 51 −0.638 ,0.001
HSCL-25 wHOQOL psychiatric 9 months 51 −0.622 ,0.001
HSCL-25 wHOQOL social 9 months 51 −0.225 NS
HSCL-25 wHOQOL environment 9 months 51 −0.405 ,0.01
Oga et al39 HAD-D SGRQ total 1 year 128 0.471 ,0.001
HAD-D CRQ total 1 year 128 −0.581 ,0.001
HAD-D SGRQ total 5 years 72 0.473 ,0.001
HAD-D CRQ total 5 years 72 −0.549 ,0.001
Coventry et al40 HAD-D 
HAD-D
SGRQ total 
SGRQ total
3 months 
1 year
79 
62
0.517 
0.636
,0.001 
,0.001
Abbreviations: HSCL-25, Hopkins Symptoms Checklist; SGRQ, St George’s Respiratory Questionnaire; CRQ, Chronic Respiratory Questionnaire; HAD-D, Hospital Anxiety 
and Depression Scale depression subscale; HRQoL, health-related quality of life; NS, not significant; WHOQOL-BREF, World Health Organization Quality of Life Instrument.
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Strengths and limitations
This review has several strengths. Firstly, the search was 
designed to take a broad approach to the identification of 
papers that included depression and anxiety. Terms to iden-
tify both clinically significant and subclinical depression and 
anxiety symptoms were included. Secondly, the search strat-
egy for this review was designed to find cohort studies that 
had investigated the strength of the longitudinal association 
between depression, anxiety or panic disorder, and HRQoL 
in COPD which has not been done before. The decision to 
exclude studies where samples had been exposed to any 
intervention was made to ensure that any prospective change 
in HRQoL would be unconfounded with treatment effects. 
Furthermore, cohort studies are often easier to recruit into 
than randomized controlled trials, and therefore the samples 
may be less open to threats to their external validity.51 The 
search resulted in identification of 380 studies, a relatively 
small number for a systematic review. Therefore, it is pos-
sible that inclusion of methodological terms to locate only 
prospective studies may have reduced the sensitivity of the 
search. However, we are confident that our search identi-
fied all potentially eligible relevant studies and we believe 
we have identified at least two studies40,45 not included in 
a recent meta-analysis of studies that measured factors 
influencing HRQoL in COPD.25 Finally, the detection of 
between-study variance can be interpreted as a positive 
finding since the very likely present heterogeneity has been 
identified and appropriately accounted for using a random 
effects model.52
This review has some weaknesses. Firstly, we used a qual-
ity scoring system that presents an overall quality score which 
rates methodological weaknesses equally. There is a lack of 
empirical support for the assumption that all methodological 
weaknesses have equal weight. Therefore, we present details 
of the performance of each study on each methodological 
criterion and also highlight the three criteria deemed to be 
most important for longitudinal studies.34 The quality review 
highlighted several methodological issues with the studies 
eligible for inclusion in this review. One of the studies that 
was rated as the highest quality42 was not eligible for inclusion 
in the meta-analysis because data on the longitudinal associa-
tion between baseline depression or anxiety and HRQoL at 
follow-up were not available. The three studies that did report 
this data were of varying quality, with two meeting two of the 
specified quality requirements,40,43 and one failing to meet 
any.39 Only one study40 provided information on sampling and 
recruitment procedures and recruitment response rates.
Therefore, it was not possible to evaluate whether the 
sampling method was open to selection bias in the included 
studies of lower quality. Furthermore, none of the studies pro-
vide any comparison between those who were and those who 
were not recruited, making evaluation of possible response 
bias impossible. The inconsistent reporting of response and 
attrition bias throughout the studies has implications for the 
Study name Statistics for each  study
Correlation
Oga et al39 SGRQ total 0.471 0.324 0.596 5.717 0.000
Andenaes et al43 SGRQ Impact 0.249 −0.029 0.491 1.762 0.078
Coventry et al40 SGRQ total 0.636 0.461 0.763 5.818 0.000
0.478 0.373 0.571 7.940 0.000
Negative association  Positive association
−1.00 −0.50 0.00 0.50 1.00
Lower
Limit
Upper
Limit Z-value P-value
Correlation and 95% CIOutcome
Figure 2 Forest plot of the longitudinal effect of depression on health-related quality of life in COPD.
Notes: Heterogeneity c2=6.60 (df=2); P=0.037; I2=69.7%.
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; SGRQ, St George’s Respiratory Questionnaire.
Table 4 Longitudinal correlations between anxiety and HRQoL in chronic obstructive pulmonary disease
Reference Anxiety  
measure
HRQoL  
measure
Length of  
follow-up
Sample  
size
Correlation 
(r)
P-value
Oga et al39 HAD-A SGRQ total 1 year 128 0.412 ,0.001
HAD-A CRQ total 1 year 128 −0.534 ,0.001
HAD-A SGRQ total 5 years 72 0.505 ,0.001
HAD-A CRQ total 5 years 72 −0.641 ,0.001
Coventry et al40 HAD-A 
HAD-A
SGRQ total 
SGRQ total
3 months 
1 year
79 
62
0.369 
0.258
0.002 
0.052
Abbreviations: HAD-A, Hospital Anxiety and Depression Scale anxiety subscale; HRQoL, health-related quality of life; SGRQ, St George’s Respiratory Questionnaire; 
CRQ, Chronic Respiratory Questionnaire.
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inferences that can be drawn from this review. It may be that 
the results cannot be generalized to older COPD patients 
because they were less likely to complete follow-up in 
two studies,42,44 although these studies were not eligible for 
inclusion in the meta-analysis. All of the included studies 
used validated measures of quality of life and psychological 
factors. However, one study43 that used the Hopkins Symptom 
Checklist (HSCL-25) modified the measure, removing two of 
the items relating to suicidal ideation and loss of libido, which 
are symptoms commonly associated with depression. This 
reduces the validity of the measure and may have resulted in 
an underestimate of the prevalence of depressive symptoms 
in this sample. Unpublished studies were not included in 
this review, which may have introduced publication bias 
into this review because studies that report higher effect 
sizes are more likely to be published.53 Where total scores 
for HRQoL measures were not available for meta-analysis, 
the most appropriate subscale was chosen. In the case of one 
paper,43 the SGRQ impact subscale was chosen because it 
provides a measure of social functioning and psychological 
disturbance that would maximize any observed association 
between depression and HRQoL. We did not formally test 
for publication bias in this review due to the small number of 
studies eligible for inclusion.54 Finally, one of the assumptions 
made in random effects meta-analysis is that study effects 
should be normally distributed. This is not always easy to 
confirm when the number of studies included in the model 
is small. However, methods have been found to be relatively 
robust even under extreme distributional scenarios.55
Implications for research and practice
The results of the meta-analysis show that depression and 
anxiety predict future HRQoL. These findings are consistent 
with the results of a recently published systematic review and 
meta-analysis that assessed the association between psycho-
logical and symptom-based factors and HRQoL in COPD 
patients.25 Tsiligianni et al found that depression, anxiety, 
exercise, and dyspnea were more highly correlated with 
HRQoL in COPD than FEV
1
,25 but this finding was based 
only on cross-sectional studies and therefore did not include 
several studies which were eligible to be included for meta-
analysis in our review.39,40,43 Our review, which is the first to 
only include longitudinal studies, has further advanced our 
knowledge of the association between depression and anxiety 
and HRQoL in COPD by showing that depression and anxiety 
are correlated with prospective HRQoL. Unfortunately, we 
were not able to compare the association between depres-
sion and anxiety and HRQoL with that of FEV
1
 because the 
necessary data were not reported in the published papers. 
Two authors were contacted39,40 and invited to provide the 
correlations between FEV
1
 and HRQoL. However, only one 
author responded, so the analysis could not be completed. 
This should be a priority for future longitudinal research in 
this area.
Future studies would be improved by including other 
common mental health problems that are prevalent in COPD. 
Panic disorder has a prevalence in COPD estimated to be ten 
times that of the prevalence in the general population.56,57 
Panic disorder is known to have a significant negative 
impact on quality of life in the general population58,59 and 
in patients with long-term conditions such as heart failure60 
and diabetes.61 However, no studies were identified in this 
review that had considered the impact of panic attacks or 
panic disorder in COPD. Panic attacks and panic disorder 
comorbid with COPD have been found to cause greater levels 
of distress relating to physical health,62 and to predict worse 
health outcomes, including increased hospital admissions63 
and poorer functional status.64 Therefore, it is important to 
investigate if panic disorder is a significant driver of HRQoL 
in COPD because it may be a more important predictor than 
depression or generalized anxiety.
The findings of this review highlight the importance of 
regularly assessing patient-centered outcomes such as HRQoL 
in people with COPD, regardless of their disease severity as 
measured by lung function. HRQoL is an important marker 
of functioning, and is potentially mediated by extrapulmonary 
Study name Statistics for each  study
Correlation
Oga et al39 SGRQ total 0.412 0.257 0.546 4.897 0.000
Coventry et al40 SGRQ total 0.258 0.011 0.476 2.047 0.041
0.364 0.233 0.482 5.191 0.000
Negative association Positive association
−1.00 −0.50 0.00 0.50 1.00
Lower
Limit
Upper
Limit Z-value P-value
Correlation and 95% CIOutcome
Figure 3 Forest plot of the longitudinal effect of anxiety on health-related quality of life in COPD.
Notes: Heterogeneity c2=1.22 (df=1); P=0.269; I2=18.3%.
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; SGRQ, St George’s Respiratory Questionnaire; HAD-A, Hospital Anxiety and 
Depression Scale anxiety subscale.
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features of COPD such as anxiety and depression. Whereas 
self-management and education have had limited impact on 
the psychological health of COPD patients,65–67 case manage-
ment that draws on integrated and collaborative approaches 
has been shown to reduce depression and improve physical 
health in people with diabetes and coronary heart disease,68 
although their effectiveness and safety in COPD is unknown.69 
As well as scope for testing the acceptability and effective-
ness of collaborative care models in COPD, there is also a 
need to test mediational models proposing that psychological 
processes and improvements in psychological health predict 
improvements in HRQoL and possibly improve physical health 
outcomes and responses to rehabilitation.70
Conclusion
The findings of this review confirm that there is an associa-
tion between depression, anxiety, and HRQoL that endures 
over time. However, this longitudinal analysis does not show 
cause and effect between depression and anxiety and future 
HRQoL. Future studies should identify psychological pre-
dictors of poor HRQoL in well designed prospective cohorts 
with a view to isolating the mediating role played by anxiety 
disorders and depression.
Acknowledgments
This study was funded by the National Institute for Health 
Research under its Programme Grants for Applied Research 
programme (grant RP-PG-0707-10162), by the University of 
Manchester (PB, EK, PAC), and the National Institute for Health 
Research and Care (CLAHRC) for the South West Peninsula 
(CD). This article presents independent research funded by 
the National Institute for Health Research (NIHR) under its 
Programme Grants for Applied Research scheme (RP-PG-0707-
10162). The views expressed are those of the authors and not 
necessarily those of the NHS, the NIHR or the Department of 
Health. We wish to acknowledge the contribution of authors 
who provided additional information on their studies, namely, 
C Engstrom and T Oga.
Author contributions
AB: planned and designed this systematic review and 
 meta-analysis, the inclusion and exclusion criteria, and 
search strategies; conducted the search, identified eligible 
papers, extracted the data, and performed the meta-analysis; 
interpreted findings and wrote the drafts of the paper for 
 submission; coordinated with coauthors to collate com-
ments; and wrote the final draft of the paper. CD: supervised 
the planning and design of this review and meta-analysis; 
assisted in the development of inclusion and exclusion criteria, 
development of search strategies, meta-analysis, interpretation 
of findings, and drafting of the paper; and approved the final 
version of the paper. EG: supervised the planning and design 
of this review and meta-analysis; assisted in the development 
of inclusion and exclusion criteria, development of search 
strategies, meta-analysis, interpretation of findings, and 
drafting of the paper; and approved the final version of the 
paper. PB: supervised the planning and design of this review 
and meta-analysis; assisted in the development of inclusion 
and exclusion criteria, development of search strategies, meta-
analysis, interpretation of findings, and drafting of the paper; 
and approved the final version of the paper. EK: supervised 
the planning and design of this review and meta-analysis; 
assisted in the development of inclusion and exclusion criteria, 
development of search strategies, meta-analysis, interpretation 
of findings, and drafting of the paper; and approved the final 
version of the paper. CA: Made a substantial contribution to 
the acquisition and interpretation of data by assisting in data 
extraction, reviewing the quality of included papers, drafting 
of the paper, making critical revisions to the final draft and 
approved the final version of the paper. PAC: supervised the 
planning and design of this review and meta-analysis, assisted 
in the development of inclusion and exclusion criteria, devel-
opment of search strategies,  meta-analysis, interpretation of 
findings, drafting of the paper; and approved the final version 
of the paper.
Disclosure
None of the authors had competing interests to declare.
References
1. World Health Organization. Global surveillance, prevention and control of 
chronic respiratory disease: a comprehensive approach. Geneva,  Switzerland: 
World Health Organization; 2007. Available from: http://www.who.int/
gard/publications/GARD_Manual/en/. Accessed March 11, 2014.
2. Agusti A, Calverly P, Celli B, et al; Evaluation of COPD Longitudinally 
to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. 
Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir 
Res. 2010;11:122.
3. Huertas A, Palange P. COPD: a multifactorial systemic disease. Ther 
Adv Respir Dis. 2011;5:217–224.
4. Jenkins C, Rodriguez-Roisin R. Quality of life, stage severity and COPD. 
Eur Respir J. 2009;33:953–955.
5. Bakas T, McMlennon S, Carpenter J, et al. Systematic review of 
health- related quality of life outcomes. Health Qual Life Outcomes. 
2012;10:134.
6. Moriarty D, Zack M, Kobau R. The Centers for Disease Control and 
 Prevention’s Health Days Measures – population tracking of percieved 
physical and mental health over time. Health Qual Life Outcomes. 
2003;1:37.
7. Curtis J, Patrick D. The assessment of health status among patients with 
COPD. Eur Respir J. 2003;21:36s–45s.
8. Jones P, Brusselle G, Dal Negro R, et al. Health-related quality of life in 
patients by COPD severity within primary care in Europe. Respir Med. 
2011;105:57–66.
International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
511
Depression, anxiety, and health-related quality of life in COPD
 9. Weatherall M, Marsh S, Shirtcliffe P, Williams M, Travers J, Beasly R. 
Quality of life measured by the St George’s Respiratory Questionnaire 
and spirometry. Eur Respir J. 2009;33:1025–1030.
 10. Monteagudo M, Rodriguez-Blanco T, Llagostera M, et al. Factors 
 associated with changes in quality of life of COPD patients: a prospec-
tive study in primary care. Respir Med. 2013;107:1589–1597.
 11. Garrido PC, de Miguel Diez J, Gutierrez JR, et al. Negative impact of 
chronic obstructive pulmonary disease on the health-related quality 
of life of patients. Results of the EPIDEPOC study. Health Qual Life 
Outcomes. 2006;4:31.
 12. Donaldson GC, Wilkinson TMA, Hurst JR, Perera WR, Wedzicha JA. 
Exacerbations and time spent outdoors in chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med. 2005;171:446–451.
 13. Almagro P, Barreiro B, Ochoa de Echaguen A, et al. Risk factors for 
hospital readmissions in patients with chronic obstructive pulmonary 
disease. Respiration. 2006;73:311–317.
 14. Gudmundsson G, Gislason T, Janson C, et al. Risk factors for 
 rehospitalistion in COPD: role of health status, anxiety and depression. 
Eur Respir J. 2005;26:414–419.
 15. Osman I, Godden D, Friend J, Legge J, Douglas J. Quality of life and 
hospital re-admission in patients with chronic obstructive pulmonary 
disease. Thorax. 1997;52:67–71.
 16. Almagro P, Calbo E, Ochoa de Echaguen A, et al. Mortality after 
admission for COPD. Chest. 2002;121:1441–1448.
 17. Domingo-Salvany A, Lamarca R, Ferrer M, et al. Health-related quality 
of life and mortality in male patients with chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med. 2002;166:680–685.
 18. Crockett A, Cranston J, Moss J, Alpers J. The impact of anxiety, 
 depression and living alone in chronic obstructive pulmonary disease. 
Qual Life Res. 2002;11:309–316.
 19. Al-shair K, Dockry R, Mallia-Milanes B, Kolsom U, Singh D, Vetsbo J. 
Depression and its relationship with poor exercise capacity, BODE index 
and muscle wasting in COPD. Respir Med. 2009;103:1572–1579.
 20. Martinez Frances M, Tordera M, Fuster A, Martinez Moragon E, 
Torrero L. [Impact of baseline and induced dyspnea on the quality of 
life of patients with COPD]. Arch Bronconeumol. 2008;44:127–134. 
Spanish.
 21. Quint J, Baghai-Ravary R, Donaldson G, Wedzicha J. Relationship 
between depression and exacerbations in COPD. Eur Respir Rev. 
2008;32:53–60.
 22. Di Marco F, Verga M, Reggente M, et al. Anxiety and depression in 
COPD patients: the roles of gender and disease severity. Respir Med. 
2006;100:1767–1774.
 23. Peruzza S, Sergi G, Vianello A, et al. Chronic obstructive pulmonary 
disease (COPD) in elderly subjects: impact on functional status and 
quality of life. Respir Med. 2003;97:612–617.
 24. Balcells E, Gea J, Ferrer J, et al. Factors affecting the relationship 
between psychological status and quality of life in COPD patients. 
Health Qual Life Outcomes. 2010;8:108.
 25. Tsiligianni I, Kocks J, Tzanakis N, Siafakas N, van der Molen T. 
 Factors that influence disease-specific quality of life or health status in 
patients with COPD: a systematic review and meta-analysis or Pearson 
 correlations. Prim Care Respir J. 2011;20:257–268.
 26. Iguchi A, Senjyu H, Hayashi Y, et al. Realtionship between depression 
in patients with COPD and the percent of predicted FEV1, BODE index, 
and health-related quality of life. Respir Care. 2013;58:334–339.
 27. Boros P, Lubinski W. Health state and quality of life in patients 
with chronic obstructive pulmonary disease (COPD) in Poland: 
a study using the EuroQoL-5D questionnaire. Pol Arch Med Wewn. 
2012;122:73–81.
 28. Stewart A, Hays R, Ware J. The MOS Short Form General Health 
Survey. Med Care. 1988;26:724–735.
 29. Kim H, Kunik M, Molinari V, et al. Functional impairment in COPD 
patients: the impact of anxiety and depression. Psychosomatics. 
2000;41:465–471.
 30. Felker B, Katon W, Hedrick S, et al. The association between  depressive 
symptoms and health status in patients with chronic pulmonary disease. 
Gen Hosp Psychiatry. 2001;23:56–61.
 31. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items 
for systematic reviews and meta-analysis: the PRISMA statement. BMJ. 
2009;339:b2535.
 32. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy 
for the Diagnosis, Management, and Prevention of Chronic Obstruc-
tive Pulmonary Disease. 2010. Available from: http://www.goldcopd.
org/uploads/users/files/GOLDReport_April112011.pdf. Accessed 
March 11, 2014.
 33. Centre for Reviews and Dissemination University of York.  Systematic 
Reviews. CRD’s guidance for undertaking reviews in health 
care, 2009. Available from: http://www.york.ac.uk/inst/crd/pdf/
Systematic_Reviews.pdf. Accessed March 11, 2014.
 34. Thomos B, Ciliska D, Dobbins M, Micucci S. A process for 
 systematically reviewing the literature: providing the research evidence 
for public health nursing interventions. Worldviews Evid Based Nurs. 
2004;1:176–184.
 35. Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory 
Questionnaire. Respir Med. 1991;85:25–31.
 36. Hedges L, Olkin I. Statistical Methods for Meta-Analysis. Orlando, FL, 
USA: Academic Press; 1985.
 37. Borenstein M, Hedges L, Higgins J, Rothstein H. Introduction to 
 Meta-Analysis. 1st ed. New York, NY, USA: Wiley; 2009.
 38. Lipsey M, Wilson D. Practical Meta-Analysis. London, UK: Sage 
Publications; 2001.
 39. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. 
 Longitudinal deteriorations in patient reported outcomes in patients 
with COPD. Respir Med. 2007;101:146–153.
 40. Coventry P, Gemmell I, Todd C. Psychosocial risk factors for hospital 
readmission in COPD patients on early discharge services: a cohort 
study. BMC Pulm Med. 2011;11:49.
 41. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency 
in meta-analysis. BMJ. 2003;327:557–560.
 42. Ng T, Niti M, Tan W, Cao Z, Ong K, Eng P. Depressive  symptoms 
and chronic obstructive pulmonary disease. Arch Intern Med. 
2007;167:60–67.
 43. Andenaes R, Moum T, Kalfoss M, Wahl A. Changes in health status, 
psychological distress, and quality of life in COPD patients after 
 hospitalisation. Qual Life Res. 2006;15:249–257.
 44. Engstrom C, Persson L, Larsson S, Sullivan M. Health related quality 
of life in COPD: why both disease-specific and generic measures should 
be used. Eur Respir J. 2001;18:69–76.
 45. Graydon J, Ross E, Webster P, Goldstein R, Avendano M. Predictors 
of functioning of patients with chronic obstructive pulmonary disease. 
Heart Lung. 1995;24:369–375.
 46. Guyatt GH, Berman LB, Townsend M, Pugslet SO, Chamber LW. 
A measure of quality of life for clinical trials in chronic lung disease. 
Thorax. 1987;42:773–778.
 47. Gilson B, Gilson J, Bergner M, et al. The sickness impact profile. 
Development of an outcome measure of health care. Am J Public Health. 
1975;65:1304–1310.
 48. Zigmond A, Snaith R. The Hospital Anxiety and Depression Scale. 
Acta Psychiatr Scand. 1983;67:361–370.
 49. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The 
Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. 
Behav Sci. 1974;19:1–15.
 50. McNair DM, Lorr M, Droppleman LF. Profile of Mood States. San 
Diego, CA, USA: Educational and Industrial Testing Service; 1981.
 51. Patel M, Doku V, Tennakoon L. Challenges in recruitment of research 
participants. Adv Psychiatr Treat. 2003;9:229–238.
 52. Kontopantelis E, Springate D, Reeves D. A re-analysis of the Cochrane 
Library data: the dangers of unobserved heterogeneity in meta-analysis. 
PLoS One. 2013;8(7):e69930.
 53. Dickersin K. Publication bias: recognizing the problem, understanding 
its origins and scope, and preventing harm. In: Rothstein H, Sutton A, 
Borenstein M, editors. Publication Bias in Meta-Analysis: Prevention, 
Assessment and Adjustments. New York, NY, USA: Wiley; 2005.
 54. Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta- anlaysis 
detected by a simple, graphical test. BMJ. 1997;315:629–634.
International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-copd-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of COPD 2014:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
512
Blakemore et al
 55. Kontopantelis E, Reeves D. Performance of statistical methods for 
meta-analysis when true study effects are non-normally distributed: 
a simulation study. Stat Methods Med Res. 2012;21:409–426.
 56. Livermore N, Sharpe L, McKenzie D. Prevention of panic attacks and 
panic disorder in COPD. Eur Respir J. 2010;35:557–563.
 57. Willgoss T, Yohannes A. Anxiety disorders in patients with chronic 
obstructive pulmonary disease: a systematic review. Respir Care. 
2013;58:858–866.
 58. Davidoff J, Chistensen S, Khalili D, Nguyen J, Ishak W. Quality of life 
in panic disorder: looking beyond symptom remission. Qual Life Res. 
2012;21:945–959.
 59. Sherbourne C, Wells K, Judd L. Functioning and well-being of patients 
with panic disorder. Am J Psychiatry. 1996;153:213–218.
 60. Muller-Tasch T, Frankenstein L, Holzapfel N, et al. Panic disorder 
in patients with chronic heart failure. J Psychosom Res. 2008;64: 
299–303.
 61. Ludman E, Katon W, Russon J, et al. Panic episodes among patients 
with diabetes. Gen Hosp Psychiatry. 2006;28:475–481.
 62. Dowson C, Kuijer R, Town I, Mulder R. Impact of panic disorder upon 
self-management educational goals in chronic obstructive pulmonary 
disease. Chron Respir Dis. 2010;7:83–90.
 63. Yellowlees P, Alpers J, Bowden J, Bryant G, Ruffin R. Psychiatric 
morbidity in patients with chronic airflow obstruction. Med J Aust. 
1987;146:305–307.
 64. Moore C, Zebb B. Functional status in chronic obstructive pulmo-
nary disease: the moderating effects of panic. Int J Rehabil Health. 
1998;4:83–93.
 65. Effing T, Monninkhof E, van der Valk P, Zeilhuis G, vn der Palen J, 
Zwerink M. Self-management education in chronic obstructive 
pulmonary disease (COPD). Cochrane Database Syst Rev. 2007;4: 
CD002990.
 66. McGeoch G, Willsman K, Dowson C, et al. Self-management plans in 
the primary care of patients with chronic obstructive pulmonary disease. 
Respirology. 2006;11:611–618.
 67. Coventry P, Bower P, Keyworth C, et al. The effect of complex 
interventions on depression and anxiety in chronic obstructive pul-
monary disease: systematic review and meta-analysis. PLoS One. 
2013;8:e60532.
 68. Katon W, Lin E, Von Korff M, et al. Collaborative care for patients with 
depression and chronic illness. N Engl J Med. 2010;363:2611–2620.
 69. Fan V, Gaziano M, Lew R, et al. A comprehensive care  management 
program to prevent chronic obstructive pulmonary disease 
 hospitalizations: a randomized controlled trial. Ann Intern Med. 
2012;156:673–683.
 70. Boersma S, Maes S, Joekes K, Dusseldorp E. Goal processes in rela-
tion to goal attainment: prediciting health-related quality of life in 
myocardial infarction patients. J Health Psychol. 2006;11:927–941.
